PR1 vaccination in myeloid malignancies

References

• Barnes DW, Loutit JF. Treatment of murine leukaemia with X-rays and homologous bone marrow. II. 1957. Br. J. Haematol.3, 241–252 (2008).
   Google Scholar
• Weiden PL, Flournoy N, Thomas ED et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med.300, 1068–1073 (1979).
   PubMed Web of Science ®Google Scholar
• Weiden PL, Sullivan KM, Flournoy N, Storb R, Thomas ED. Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation. N. Engl. J. Med.304, 1529–1533 (1981).
   PubMed Web of Science ®Google Scholar
• Horowitz MM, Gale RP, Sondel PM et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood75, 555–562 (1990).
   PubMed Web of Science ®Google Scholar
• Antin JH. Graft-versus-leukemia: no longer an epiphenomenon. Blood82, 2273–2277 (1993).
   PubMed Web of Science ®Google Scholar
• Drobyski WR, Keever CA, Roth MS et al. Salvage immunotherapy using donor leukocyte infusions as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation: efficacy and toxicity of a defined T-cell dose. Blood82, 2310–2318 (1993).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood76, 2462–2465 (1990).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Schattenberg A, Goldman JM et al. Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia. Blood86, 2041–2050 (1995).
   PubMed Web of Science ®Google Scholar
• Johnson BD, Drobyski WR, Truitt RL. Delayed infusion of normal donor cells after MHC-matched bone marrow transplantation provides an antileukemia reaction without graft-versus-host disease. Bone Marrow Transplant.11, 329–336 (1993).
   PubMed Web of Science ®Google Scholar
• Kolb HJ, Gunther W, Schumm M et al. Adoptive immunotherapy in canine chimeras. Transplantation63, 430–436 (1997).
   Google Scholar
• Michalek J, Collins RH, Durrani HP et al. Definitive separation of graft-versus-leukemia- and graft-versus-host-specific CD4+ T cells by virtue of their receptor β loci sequences. Proc. Natl Acad. Sci. USA100, 1180–1184 (2003).
   PubMed Web of Science ®Google Scholar
• Andre-Schmutz I, Le DF, Hacein-Bey-Abina S et al. Immune reconstitution without graft-versus-host disease after haemopoietic stem-cell transplantation: a Phase 1/2 study. Lancet360, 130–137 (2002).
   PubMed Web of Science ®Google Scholar
• Mielke S, Nunes R, Rezvani K et al. A clinical scale selective allodepletion approach for the treatment of HLA-mismatched and matched donor-recipient pairs using expanded T lymphocytes as antigen-presenting cells and a TH9402-based photodepletion technique. Blood111(8), 4392–4402 (2008).
   PubMed Web of Science ®Google Scholar
• Solomon SR, Mielke S, Savani BN et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood106, 1123–1129 (2005).
   PubMed Web of Science ®Google Scholar
• De Plaen E, Lurquin C, Van PA et al. Immunogenic (tum-) variants of mouse tumor P815: cloning of the gene of tum- antigen P91A and identification of the tum- mutation. Proc. Natl Acad. Sci. USA85, 2274–2278 (1988).
   PubMed Web of Science ®Google Scholar
• van der Bruggen P, Traversari C, Chomez P et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science254, 1643–1647 (1991).
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Kant S et al. Chronic myelogenous leukemia shapes host immunity by selective deletion of high-avidity leukemia-specific T cells. J. Clin. Invest111, 639–647 (2003).
   PubMed Web of Science ®Google Scholar
• Dengler R, Munstermann U, al-Batran S et al. Immunocytochemical and flow cytometric detection of proteinase 3 (myeloblastin) in normal and leukaemic myeloid cells. Br. J. Haematol.89, 250–257 (1995).
   PubMed Web of Science ®Google Scholar
• Fujiwara H, El Ouriaghli F, Grube M et al. Identification and in vitro expansion of CD4+ and CD8+ T cells specific for human neutrophil elastase. Blood103, 3076–3083 (2004).
   PubMed Web of Science ®Google Scholar
• Bories D, Raynal MC, Solomon DH, Darzynkiewicz Z, Cayre YE. Down-regulation of a serine protease, myeloblastin, causes growth arrest and differentiation of promyelocytic leukemia cells. Cell59, 959–968 (1989).
   PubMed Web of Science ®Google Scholar
• Lane AA, Ley TJ. Neutrophil elastase cleaves PML–RARα and is important for the development of acute promyelocytic leukemia in mice. Cell115, 305–318 (2003).
   PubMed Web of Science ®Google Scholar
• Yong ASM, Szydlo RM, Goldman JM, Apperley JF, Melo JV. Molecular profiling of CD34+ cells in CML patients identifies low expression of CD7 with high expression of proteinase 3 or elastase as predictors of longer survival. Blood107(1), 205–212 (2006).
   PubMed Web of Science ®Google Scholar
• Yong AS, Rezvani K, Savani BN et al. High PR3 or ELA2 expression by CD34+ cells in advanced-phase chronic myeloid leukemia is associated with improved outcome following allogeneic stem cell transplantation and may improve PR1 peptide-driven graft-versus-leukemia effects. Blood110, 770–775 (2007).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Price D, Brenchley J et al. Transfer of PR1-specific T-cell clones from donor to recipient by stem cell transplantation and association with GvL activity. Cytotherapy9, 245–251 (2007).
   PubMed Web of Science ®Google Scholar
• Molldrem J, Dermime S, Parker K et al. Targeted T-cell therapy for human leukemia: cytotoxic T lymphocytes specific for a peptide derived from proteinase 3 preferentially lyse human myeloid leukemia cells. Blood88, 2450–2457 (1996).
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Clave E, Jiang YZ et al. Cytotoxic T lymphocytes specific for a nonpolymorphic proteinase 3 peptide preferentially inhibit chronic myeloid leukemia colony-forming units. Blood90, 2529–2534 (1997).
   PubMed Web of Science ®Google Scholar
• Molldrem JJ, Lee PP, Wang C et al. Evidence that specific T lymphocytes may participate in the elimination of chronic myelogenous leukemia. Nat. Med.6, 1018–1023 (2000).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Grube M, Brenchley JM et al. Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantation. Blood102, 2892–2900 (2003).
   PubMed Web of Science ®Google Scholar
• Scheibenbogen C, Letsch A, Thiel E et al. CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemia. Blood100, 2132–2137 (2002).
   PubMed Web of Science ®Google Scholar
• Gannage M, Abel M, Michallet AS et al.Ex vivo characterization of multiepitopic tumor-specific CD8 T cells in patients with chronic myeloid leukemia: implications for vaccine development and adoptive cellular immunotherapy. J. Immunol.174, 8210–8218 (2005).
   PubMed Web of Science ®Google Scholar
• Papadopoulos KP, Suciu-Foca N, Hesdorffer CS et al. Naturally processed tissue- and differentiation stage-specific autologous peptides bound by HLA class I and II molecules of chronic myeloid leukemia blasts. Blood90, 4938–4946 (1997).
   PubMed Web of Science ®Google Scholar
• Knights AJ, Weinzierl AO, Flad T et al. A novel MHC-associated proteinase 3 peptide isolated from primary chronic myeloid leukaemia cells further supports the significance of this antigen for the immunotherapy of myeloid leukaemias. Leukemia20, 1067–1072 (2006).
   Google Scholar
• Fujiwara H, Sconocchia G, Melenhorst J et al. Tissue-restricted T cell alloresponses across HLA barriers: selection and identification of leukemia-restricted CTL in HLA-mismatched stimulator–responder pairs. Bone Marrow Transplant.32, 3711–378 (2003).
   Google Scholar
• Apenberg S, Andrassy K, Worner I et al. Antibodies to neutrophil elastase: a study in patients with vasculitis. Am. J. Kidney Dis.28, 178–185 (1996).
   Google Scholar
• Ballieux BE, van der Burg SH, Hagen EC et al. Cell-mediated autoimmunity in patients with Wegener’s granulomatosis (WG). Clin. Exp. Immunol.100, 186–193 (1995).
   PubMedGoogle Scholar
• Brouwer E, Stegeman CA, Huitema MG, Limburg PC, Kallenberg CG. T cell reactivity to proteinase 3 and myeloperoxidase in patients with Wegener’s granulomatosis (WG). Clin. Exp. Immunol.98, 448–453 (1994).
   PubMedGoogle Scholar
• Gallicchio MC, Savige JA. Detection of anti-myeloperoxidase and anti-elastase antibodies in vasculitides and infections. Clin. Exp. Immunol.84, 232–237 (1991).
   Google Scholar
• Griffith ME, Coulthart A, Pusey CD. T cell responses to myeloperoxidase (MPO) and proteinase 3 (PR3) in patients with systemic vasculitis. Clin. Exp. Immunol.103, 253–258 (1996).
   PubMed Web of Science ®Google Scholar
• Tervaert JW, Mulder L, Stegeman C et al. Occurrence of autoantibodies to human leucocyte elastase in Wegener’s granulomatosis and other inflammatory disorders. Ann. Rheum. Dis.52, 115–120 (1993).
   Google Scholar
• Gao L, Xue SA, Hasserjian R et al. Human cytotoxic T lymphocytes specific for Wilms’ tumor antigen-1 inhibit engraftment of leukemia-initiating stem cells in non-obese diabetic-severe combined immunodeficient recipients. Transplantation75, 1429–1436 (2003).
   PubMed Web of Science ®Google Scholar
• Oka Y, Elisseeva OA, Tsuboi A et al. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms’ tumor gene (WT1) product. Immunogenetics51, 99–107 (2000).
   PubMed Web of Science ®Google Scholar
• Nieda M, Nicol A, Kikuchi A et al. Dendritic cells stimulate the expansion of bcr-abl specific CD8+ T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood91, 977–983 (1998).
   PubMed Web of Science ®Google Scholar
• ten Bosch GJ, Kessler JH, Joosten AM et al. A BCR-ABL oncoprotein p210b2a2 fusion region sequence is recognized by HLA-DR2a restricted cytotoxic T lymphocytes and presented by HLA-DR matched cells transfected with an Ii(b2a2) construct. Blood94, 1038–1045 (1999).
   PubMed Web of Science ®Google Scholar
• Yotnda P, Firat H, Garcia-Pons F et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J. Clin. Invest101, 2290–2296 (1998).
   PubMed Web of Science ®Google Scholar
• Clark RE, Dodi IA, Hill SC et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR–ABL b3a2 fusion protein. Blood98, 2887–2893 (2001).
   PubMed Web of Science ®Google Scholar
• Goulmy E. Human minor histocompatibility antigens. Curr. Opin. Immunol.8, 75–81 (1996).
   PubMed Web of Science ®Google Scholar
• Marijt WA, Heemskerk MH, Kloosterboer FM et al. Hematopoiesis-restricted minor histocompatibility antigens HA-1- or HA-2-specific T cells can induce complete remissions of relapsed leukemia. Proc. Natl Acad. Sci. USA100, 2742–2747 (2003).
   PubMed Web of Science ®Google Scholar
• Bocchia M, Gentili S, Abruzzese E et al. Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. Lancet365, 657–662 (2005).
   PubMed Web of Science ®Google Scholar
• Falkenburg JH, Wafelman AR, Joosten P et al. Complete remission of accelerated phase chronic myeloid leukemia by treatment with leukemia-reactive cytotoxic T lymphocytes. Blood94, 1201–1208 (1999).
   PubMed Web of Science ®Google Scholar
• Mailander V, Scheibenbogen C, Thiel E et al. Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity. Leukemia18, 165–166 (2004).
   PubMed Web of Science ®Google Scholar
• Oka Y, Tsuboi A, Taguchi T et al. Induction of WT1 (Wilms’ tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression. Proc. Natl Acad. Sci. USA101, 13885–13890 (2004).
   PubMed Web of Science ®Google Scholar
• Qazilbash MH, Wieder E, Rios R et al. Vaccination with the PR1 leukemia-associated antigen can induce complete remission in patients with myeloid leukemia. ASH Annual Meeting Abstracts104, 259 (2004).
   Google Scholar
• Qazilbash MH, Wieder E, Thall PF et al. PR1 peptide vaccine-induced immune response is associated with better event-free survival in patients with myeloid leukemia. Blood110, 283 (2007).
   Google Scholar
• Qazilbash MH, Wieder E, Thall PF et al. PR1 vaccine elicited immunological response after hematopoietic stem cell transplantation is associated with better clinical response and event-free survival. ASH Annual Meeting Abstracts110, 577 (2007).
   Google Scholar
• Rezvani K, Yong AS, Mielke S et al. Leukemia-associated antigen-specific T-cell responses following combined PR1 and WT1 peptide vaccination in patients with myeloid malignancies. Blood111, 236–242 (2008).
   PubMed Web of Science ®Google Scholar
• Muller-Berat N, Minowada J, Tsuji-Takayama K et al. The phylogeny of proteinase 3/myeloblastin, the autoantigen in Wegener’s granulomatosis, and myeloperoxidase as shown by immunohistochemical studies on human leukemic cell lines. Clin. Immunol. Immunopathol.70, 51–59 (1994).
   Google Scholar
• Williams RC Jr, Staud R, Malone CC et al. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener’s granulomatosis. J. Immunol.152, 4722–4737 (1994).
   PubMed Web of Science ®Google Scholar
• Spencer SJ, Burns A, Gaskin G, Pusey CD, Rees AJ. HLA class II specificities in vasculitis with antibodies to neutrophil cytoplasmic antigens. Kidney Int.41, 1059–1063 (1992).
   PubMedGoogle Scholar
• Rooney CM, Smith CA, Ng CY et al. Infusion of cytotoxic T cells for the prevention and treatment of Epstein–Barr virus-induced lymphoma in allogeneic transplant recipients. Blood92, 1549–1555 (1998).
   PubMed Web of Science ®Google Scholar
• Walter EA, Greenberg PD, Gilbert MJ et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N. Engl. J. Med.333, 1038–1044 (1995).
   PubMed Web of Science ®Google Scholar
• Monaco JJ. Pathways for the processing and presentation of antigens to T cells. J. Leukoc. Biol.57, 543–547 (1995).
   PubMed Web of Science ®Google Scholar
• Rammensee HG. Antigen presentation – recent developments. Int. Arch. Allergy Immunol.110, 299–307 (1996).
   Google Scholar
• Machiels JP, van BN, Marchand M. Peptide-based cancer vaccines. Semin. Oncol.29, 494–502 (2002).
   PubMed Web of Science ®Google Scholar
• Rosenblatt J, Avigan D. Can leukemia-derived dendritic cells generate antileukemia immunity? Exp. Rev. Vaccines5(4), 467–472 (2006).
   Web of Science ®Google Scholar
• Houtenbos I, Westers TM, Dijkhuis A et al. Leukemia-specific T-cell reactivity induced by leukemic dendritic cells is augmented by 4-1BB targeting. Clin. Cancer Res.13, 307–315 (2007).
   PubMed Web of Science ®Google Scholar
• Wiethe C, Dittmar K, Doan T, Lindenmaier W, Tindle R. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. J. Immunol.170, 2912–2922 (2003).
   Google Scholar
• Stan R, Wolchok JD, Cohen AD. DNA vaccines against cancer. Hematol. Oncol. Clin. North Am.20, 613–636 (2006).
   PubMedGoogle Scholar
• Yong ASM, Keyvanfar K, Eniafe R et al. Hematopoietic stem cells and progenitors of chronic myeloid leukemia express leukemia-associated antigens: implications for the graft-versus-leukemia effect and peptide vaccine-based immunotherapy. Leukemia (2008) (Epub ahead of print) DOI: 10.1038/leu.2008.161.
   Google Scholar
• Alpdogan O, Eng JM, Muriglan SJ et al. Interleukin-15 enhances immune reconstitution after allogeneic bone marrow transplantation. Blood105, 865–873 (2005).
   PubMed Web of Science ®Google Scholar
• Klebanoff CA, Finkelstein SE, Surman DR et al. IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells. Proc. Natl Acad. Sci. USA101, 1969–1974 (2004).
   PubMed Web of Science ®Google Scholar
• Reddy V, Winer AG, Eksioglu E et al. Interleukin 12 is associated with reduced relapse without increased incidence of graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant.11, 1014–1021 (2005).
   PubMed Web of Science ®Google Scholar
• Ashton-Rickardt PG, Bandeira A, Delaney JR et al. Evidence for a differential avidity model of T cell selection in the thymus. Cell76, 651–663 (1994).
   PubMed Web of Science ®Google Scholar
• Schild H, Rotzschke O, Kalbacher H, Rammensee HG. Limit of T cell tolerance to self proteins by peptide presentation. Science247, 1587–1589 (1990).
   PubMedGoogle Scholar
• Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell101, 455–458 (2000).
   PubMed Web of Science ®Google Scholar
• Onizuka S, Tawara I, Shimizu J et al. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res.59, 3128–3133 (1999).
   PubMed Web of Science ®Google Scholar
• Rezvani K, Mielke S, Ahmadzadeh M et al. High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood108, 1291–1297 (2006).
   PubMed Web of Science ®Google Scholar
• Litzinger MT, Fernando R, Curiel TJ et al. The IL-2 immunotoxin denileukin diftitox reduces regulatory T cells and enhances vaccine-mediated T-cell immunity. Blood110(9), 3192–3201 (2007).
   PubMed Web of Science ®Google Scholar
• >Mahnke K, Schonfeld K, Fondel S et al. Depletion of CD4+CD25+ human regulatory T cells in vivo: kinetics of Treg depletion and alterations in immune functions in vivo and in vitro. Int. J. Cancer120, 2723–2733 (2007).
   Google Scholar
• Dannull J, Su Z, Rizzieri D et al. Enhancement of vaccine-mediated antitumor immunity in cancer patients after depletion of regulatory T cells. J. Clin. Invest.115, 3623–3633 (2005).
   PubMed Web of Science ®Google Scholar
• Dudley ME, Wunderlich JR, Robbins PF et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science298, 850–854 (2002).
   PubMed Web of Science ®Google Scholar
• Riddell SR, Greenberg PD. T-cell therapy of cytomegalovirus and human immunodeficiency virus infection. J. Antimicrob. Chemother.45(Suppl. T3), 35–43 (2000).
   Google Scholar
• Berger C, Jensen MC, Lansdorp PM et al. Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates. J. Clin. Invest118, 294–305 (2008).
   PubMed Web of Science ®Google Scholar
• Xue SA, Gao L, Hart D et al. Elimination of human leukemia cells in NOD/SCID mice by WT1-TCR gene-transduced human T cells. Blood106, 3062–3067 (2005).
   PubMed Web of Science ®Google Scholar
• Stanislawski T, Voss RH, Lotz C et al. Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer. Nat. Immunol.2, 962–970 (2001).
   PubMed Web of Science ®Google Scholar
• Clay TM, Custer MC, Sachs J et al. Efficient transfer of a tumor antigen-reactive TCR to human peripheral blood lymphocytes confers anti-tumor reactivity. J. Immunol.163, 507–513 (1999).
   PubMed Web of Science ®Google Scholar
• Morgan RA, Dudley ME, Wunderlich JR et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science314, 126–129 (2006).
   PubMed Web of Science ®Google Scholar